Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma
In a paper describing small early clinical trial in advanced sarcomas “Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma”, investigators injected an investigational drug directly into sarcoma tumors. This drug activates the innate, or non-specific immune system (IT GLA-SE). They concurrently treated the patients with radiation therapy and found that this combination provided a more durable local control of the tumors than radiation therapy alone. Patients with durable local response demonstrated an increased immune cell population. Additional studies are needed, but these findings suggest that this is a promising combination in advanced STS.